|
Chỉ định và Liều dùng
Oral
Hyperlipidaemias, Mixed dyslipidaemia Adult: 1-4 mg once daily. If given w/ erythromycin or rifampicin, max dose of 1 mg or 2 mg respectively.
|
|
Suy thận
Moderate to severe (CrCl 15-60 mL/min, not on haemodialysis) and ESRD (on haemodialysis): Initial: 1 mg once daily. Max: 2 mg once daily.
|
|
Cách dùng
May be taken with or without food.
|
|
Chống chỉ định
Active liver disease including unexplained, persistent elevations in serum aminotransferase (transaminase) concentrations. Pregnancy and lactation. Concomitant use w/ ciclosporin.
|
|
Thận trọng
Patient w/ predisposing factors for myopathy; alcoholism. Renal impairment.
|
|
Tác dụng không mong muốn
Liver enzyme abnormalities, myalgia, muscle spasm, back pain, diarrhoea, constipation, pain in extremities, arthralgia, headache, dizziness, influenza, nasopharyngitis, abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, malaise, fatigue, hepatitis, jaundice, hypoaesthesia, insomnia, depression, interstitial lung disease, erectile dysfunction, cognitive impairment (e.g. memory loss and impairment, confusion, forgetfulness, amnesia).
Potentially Fatal: Myopathy and rhabdomyolysis w/ acute renal failure secondary to myoglobinuria; hepatic failure. |
|
PO: Z (Avoid)
|
|
Chỉ số theo dõi
Monitor lipid panel (total cholesterol, HDL, LDL, triglycerides), hepatic transaminase levels; creatine phosphokinase (CPK).
|
|
Tương tác
Increased bioavailability w/ erythromycin and rifampicin. Increased risk of myopathy/rhabdomyolysis w/ gemfibrozil, colchicine, niacin and other fibrates.
Potentially Fatal: Ciclosporin significantly increases pitavastatin exposure. |
|
Tương tác với thức ăn
Increased risk of liver damage w/ alcohol.
|
|
Tác dụng
Description:
Mechanism of Action: Pitavastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA), resulting in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism. Pharmacokinetics: Absorption: Bioavailability: Approx 51%. Time to peak plasma concentration: Approx 1 hr. Distribution: Plasma protein binding: >99%. Metabolism: Hepatic, mainly via glucuronidation to a lactone metabolite; marginally metabolised by CYP2C9 and to a lesser extent by CYP2C8 isoenzyme. Excretion: Mainly via faeces; urine (approx 15%). Elimination half-life: 12 hr. |
|
Bảo quản
Store between 15-30°C. Protect from light.
|
|
Phân loại MIMS
|
|
Tài liệu tham khảo
Anon. Pitavastatin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/08/2014. Buckingham R (ed). Pitavastatin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/08/2014. Livalo Tablet, Film Coated (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/08/2014. Livalo Tablets. U.S. FDA. https://www.fda.gov/. Accessed 06/08/2014. McEvoy GK, Snow EK, Miller J et al (eds). Pitavastatin Calcium. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 06/08/2014.
|
Đăng xuất
